Sleepiness and impaired daytime function are major clinical features of the sleep apnoea/ Background -Continuous positive airway pressure (CPAP) is an effective treatment hypopnoea syndrome (SAHS) 1 2 and the primary indication for treatment with continuous in patients with moderate and severe sleep apnoea/hypopnoea syndrome (SAHS), but positive airway pressure (CPAP) is to try to improve these features. There is objective evithe minimum illness severity at which patients obtain benefit from CPAP is un-dence that CPAP has beneficial effects on daytime sleepiness, cognitive performance, and clear. A study was therefore undertaken to investigate whether CPAP improves psychological well being 3-5 but these data have been gathered in patients with moderate or symptoms and daytime function in patients with mild SAHS.
ticipate because work pressure meant they with a mean body mass index of 29.8 (1.8)
General Health kg/m 2 . The subjects had a mean AHI of 11 (1) Nottingham Health Profile (NHP) Part 2 per hour slept, the mean number of micro-WAIS-R=Wechster adult intelligence scale (revised).
arousals per hour slept was 24 (3), mean minimum oxygen saturation was 86 (1)%, and the mean 4% desaturation rate was 4 (1) per hour slept. The mean baseline Epworth sleepBefore the commencement of treatment patients attended a session of familiarisation iness score was 14 (1) in the nine patients in whom it was available, and all 16 patients with the psychometric tests used in assessment to minimise learning effects across subsequent complained of both snoring and regular napping behaviour as symptoms. assessments. Before treatment subjects also underwent a CPAP titration study to establish the therapeutic pressure at which hypopnoeas and electroencephalographic arousals from  Daytime function assessments sleep were minimised. Patients were contacted two weeks into the CPAP treatment limb to Daytime function assessments as previously described and referenced 5 were obtained on check progress and were encouraged to report any problems with CPAP use so that these the last day of each treatment. Tests (table 1) were administered in a standardised order to could be managed and compliance optimised. Subjects were asked to avoid caffeinated bev-control for circadian effects. Symptoms were rated as present or absent using an eight point erages on the assessment days and were offered only decaffeinated refreshments.
questionnaire and sleepiness was assessed using the multiple sleep latency test (MSLT) 9 and the energetic arousal scale of the UWIST mood adjective checklist (UMACL). The Epworth  Subjects were prospectively recruited from con-Sleepiness Scale, 10 11 a self-rating of recent sleepiness behaviour, was obtained in addition secutive outpatients referred to the Sleep Clinic for investigation of SAHS. Entry criteria re-to the other assessments in nine patients. The cognitive tests covered a wide range of function quired two or more symptoms of SAHS 1 and an AHI in the range 5.0-14.9 per hour slept known to be affected by SAHS, including vigilance, attention and concentration, visuoduring clinical polysomnography, conducted and scored according to our usual methods. motor skill, verbal fluency, and memory. The premorbid level of cognitive function was Polysomnography included electroencephalographic (EEG), electro-oculographic (EOG), estimated at the familiarisation session using the National Adult Reading Test (NART), and electromyographic (EMG) monitoring to facilitate the evaluation of sleep quality and while the current level of general intellectual function was measured with the Digit Symbol microarousals (defined by increases in EEG frequency of 1.5 seconds or longer, coincident Substitution and Block Design subtests from the WAIS-R battery and with TrailMaking task with any duration of increased EMG activity 2 ). Breathing pauses were monitored by in-B. The NART score provided an estimate of the premorbid level of function while the WAISductance plethysmography of abdominal and thoracic respiratory movement and by ther-R subtests allowed a measurement of current level of function, the performance IQ (PIQ), mistor assessment of oronasal airflow. Hypopnoeas were defined as 10 seconds or longer to be made. By subtracting the assessed WAIS-R PIQ on each treatment from the NART of 50% reduction in respiratory movement and apnoeas as 10 seconds or longer of absent estimate of premorbid PIQ an "IQ decrement score" was obtained. Tests of attention inairflow. 6 Arterial oxygen saturation was monitored using pulse oximetry. Patients with co-cluded a 30 minute driving-based vigilance task (SteerClear), Paced Auditory Serial Addition existing neurological or sleep disorders, or residence outwith a 50 mile radius of the Test (PASAT) at two second presentation rate, the Rapid Visual Information Processing Test laboratory, were excluded.
Twenty eight subjects were invited to par-(RVIPT), and eight choice reaction time.
Verbal fluency was assessed with Borkowski's ticipate in the study, 18 of whom accepted. Of the 10 non-acceptors, four declined to par-test and memory with the Benton Revised Visual Retention Test (BVRT). Alternative treatment type as a within subject factor, and the interaction between these two factors repforms of the letters employed in the verbal fluency test and of the designs used in the resenting learning effects. This analysis, in conjunction with the study design, allows learning BVRT were administered in succeeding assessment sessions. Minor psychiatric morbidity effects to be factored out from treatment effects. Paired Wilcoxon tests were conducted was self-rated on the Hospital Anxiety and Depression Scale (HADS) and the General for interval and non-normal data. The binomial test was used to examine the distribution of Health Questionnaire-28 (GHQ-28), and quality of life on Part 2 of the Nottingham Health treatment preference, and McNemar tests to assess changes in frequency of individual sympProfile (NHP). At the final assessment subjects were asked to rate which treatment they pre-toms. Patients were split into better and poorer compliers using median effective CPAP use as ferred, weighing ease of use and treatment benefit. a cutoff point. A subanalysis comparing CPAP and placebo outcome measurements was conducted within the group that complied better with CPAP treatment. Mann-Whitney tests CPAP compliance Compliance with CPAP therapy was monitored were conducted to compare background variables in the better and poorer compliers with by reading time clocks 12 hidden within the casing of the CPAP units which measured the CPAP treatment. All statistical analyses employed two tailed p values and were performed total duration during the treatment limb that units were switched on and that CPAP was using SPSS-PC+. 13 delivered effectively to the nasal mask. Mean compliance rates for the CPAP treatment period (hours per night) were calculated.
Results   CPAP units were run for a mean (SE) of 3.2 (0.7) hours per night and used effectively for    Outcome measurements of daytime function 2.8 (0.6) hours per night.
The measurements obtained while receiving from placebo and CPAP assessments were compared. Continuous normally distributed data treatment with CPAP were compared with those obtained on placebo treatment. Neither were examined using two-way ANOVA with treatment order as a between subjects factor, objective daytime sleepiness measured by the group.bmj.com on August 15, 2017 -Published by http://thorax.bmj.com/ Downloaded from MSLT (p>0.8 (ANOVA); fig 1A) nor subjective ment order interactions, indicating learning effects, were demonstrated for SteerClear persleepiness measured on the Epworth scale were significantly improved by CPAP (p>0.9 formance (p<0.001), the WAIS-R performance IQ score (p=0.05), and verbal fluency score (ANOVA); table 2). The total symptom score ( fig 1B) was significantly lower on CPAP than (p<0.01). placebo (p<0.01, Wilcoxon), reflecting an improvement in status. Exclusion of the snoring symptom item from the total resulted in a non-   
The patient group was split by median effective significant improvement in symptom total from treatment with placebo (2.8 (0.5)) to treatment CPAP use into better and poorer compliers (n=8 in each group). The mean (SE) effective with CPAP (1.9 (0.3); p=0.16). Performance on the TrailMaking B task of mental flexibility CPAP use was 5.0 (0.6) hours per night in the more compliant users and 1.1 (0.2) hours per was significantly improved on CPAP (p=0.02 (Wilcoxon); fig 1C) but no other treatment night in the poorer users. Four patients commenced treatment with tablets in each group. effects on cognitive performance were found. Self-rated depression score on the Hospital As in the full group, those who complied better with CPAP treatment showed significant Anxiety and Depression Scale (HADS) was significantly reduced by CPAP (p=0.03 (Wil-CPAP-related improvement in symptom total score (p=0.02), TrailMaking B performance coxon); fig 1D) , corresponding to lower distress. Ten of the 16 patients preferred CPAP (p=0.04), and HADS depression rating (p= 0.04; table 2). In addition, the NHP part 2 when the factors of ease of use and treatment benefit were weighed (p>0.4), and these score was significantly reduced in patients on CPAP (p=0.03), indicating improved quality patients commenced on long term treatment with CPAP at the conclusion of the study.
of life. Six of the eight better compliers preferred CPAP treatment (p>0.2). The effects of treatment order on the variables examined were non-significant (p>0.12)
The background features of the better and poorer compliers with CPAP were compared with the exception of mean sleep onset latency (p=0.05) which did not show a significant to assess predictors of greater CPAP use. The variables that were compared included polytreatment effect. Significant treatment × treat- group.bmj.com on August 15, 2017 -Published by http://thorax.bmj.com/ Downloaded from SAHS, or may also relate to the difficulties multiple outcome measurements analysed, raising the possibility of a type 1 false positive statistical error. Such errors occur at a fresomnographic measurements, symptoms and sleepiness reported at familiarisation, and sleep quency of one in 20 comparisons. In our study 16 tests were employed and thus three sigonset latency when off CPAP (table 3) . Both microarousal index (p<0.01) and AHI (p= nificant comparisons would not be expected by chance alone. Furthermore, all three significant 0.02) were significantly higher in those who complied better with CPAP. However, there findings were in the direction of improvement with CPAP -the hypothesised direction. We was considerable overlap between better and poorer compliers in ranges for both micro-have used two tailed rather than one tailed p values to adopt a conservative statistical aparousal index (fig 2A) and AHI ( fig 2B) . There was no difference in the pretreatment proach. In addition, the improvements with CPAP are consistent with our previous findings symptom score between poor and good compliers, and no difference in sleepiness meas-in patients with a wider range of severity of SAHS. 5 We accept that further data will be urements when off CPAP between the two groups.
required to confirm these observations. The current study will allow refinement of techniques for such studies by identification of the relevant tests.
Discussion
The results of this study suggest that patients Neither objective (MSLT) nor subjective (Epworth scale) sleepiness was improved by with mild SAHS gain benefit for symptoms, cognitive performance, and psychological dis-CPAP in patients with mild SAHS. Mean sleep onset latency approached the normal range tress from CPAP. We have previously reported that CPAP improves these same measurements on both placebo and CPAP 9 while subjective sleepiness scores were increased on both plaof daytime function in patients with more severe SAHS.
5 Thus, the study extends previous find-cebo and CPAP. 11 The results with the MSLT contrast with those from studies of patients ings on the therapeutic value of CPAP to apply to symptomatic patients with 5-15 apnoeas + with "upper airway resistance syndrome" (UARS) 15 16 whose short sleep onset latencies, hypopnoeas per hour of sleep, and indicates that such patients should be given a trial of indicative of moderate or severe sleepiness before treatment, were extended into the normal CPAP therapy.
Learning effects were demonstrated on some range by CPAP. Recent studies with CPAP in patients with more severe SAHS have shown cognitive performance tests, highlighting the importance of controlling for learning in long-statistical improvement but a lack of normalisation in objective daytime sleepiness with itudinal, treatment related studies. However, the lack of effect of treatment order on variables CPAP.
3-5 Thus, the usefulness of the MSLT in treatment related studies may be questioned. improved by treatment with CPAP ensured that the balancing of treatment order employed Alternative polysomnographic tests of daytime sleepiness, such as the maintenance of wakewithin this crossover study could control for such learning effects.
fulness test which more explicitly assesses the ability to stay awake, may, as has been sugThose daytime function tests that showed improvement in patients with mild SAHS -gested, 17 prove more sensitive to treatment effects. symptoms, cognitive performance and depression ratings -were also improved by CPAP The cognitive task showing improvement with CPAP, TrailMaking B, is a test of mental in a placebo controlled study of daytime function in patients with SAHS of a wider range of flexibility requiring rapid and complex responses. Performance on this test is impaired severity, 5 confirming the sensitivity of these measurements to the effects of CPAP. In in patients with severe SAHS 3 18 and was previously found to be unimproved following patients with mild SAHS and higher levels of CPAP compliance, improvement in quality of CPAP therapy in a sample of 10 patients with SAHS. 3 The indication of CPAP related imlife was observed with CPAP treatment in our patients as well as in those with SAHS of a provement in TrailMaking B performance in the current study may reflect improved statwider range of severity.
5 Most of the patients preferred the CPAP treatment and opted to istical power with its larger sample. Alternatively, cognitive deficits may be more continue with it after the end of the study.
However, by no means all the tests of func-reversible in patients with milder SAHS in whom sleep fragmentation rather than hyption administered showed improvements in patients on CPAP. This may reflect marginal oxaemia may play the more important role in determining cognitive impairment. or selective cognitive impairment in mild group.bmj.com on August 15, 2017 -Published by http://thorax.bmj.com/ Downloaded from Our study was carried out in patients with hypopnoeas per hour of sleep. However, further controlled studies in this patient group are mild SAHS who had 5-15 apnoeas + hyporequired to help identify whether the impnoeas per hour slept, using our standard provements in daytime function are sustained, definitions for apnoeas 19 and hypopnoeas. 6 Our to identify whether other clinical features of data cannot be extrapolated to patients with SAHS are improved by CPAP, and to help UARS, 16 although it is possible that some predict which patients will use CPAP. centres will diagnose patients who satisfy our criteria for mild SAHS as having UARS. We The authors thank Glaxo for their provision of placebo tablets suspect that this is particularly a problem with and ResCare for their donation of CPAP units for use in this study. We gratefully acknowledge the contributions of the the definition of hypopnoea which varies be-nursing, technical, and administrative staff of the Scottish Natween centres and with different sensors. 
